PL3061771T3 - Nowy peptyd o czterech połączonych epitopach dla ctl - Google Patents

Nowy peptyd o czterech połączonych epitopach dla ctl

Info

Publication number
PL3061771T3
PL3061771T3 PL14856540T PL14856540T PL3061771T3 PL 3061771 T3 PL3061771 T3 PL 3061771T3 PL 14856540 T PL14856540 T PL 14856540T PL 14856540 T PL14856540 T PL 14856540T PL 3061771 T3 PL3061771 T3 PL 3061771T3
Authority
PL
Poland
Prior art keywords
novel
ctl epitope
peptide
joined
joined peptide
Prior art date
Application number
PL14856540T
Other languages
English (en)
Inventor
Satoshi Fukaya
Toshihiro OSADA
Hiroshi Wada
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3061771T3 publication Critical patent/PL3061771T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
PL14856540T 2013-10-21 2014-10-20 Nowy peptyd o czterech połączonych epitopach dla ctl PL3061771T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013218524 2013-10-21
JP2014155132 2014-07-30
PCT/JP2014/077807 WO2015060235A1 (ja) 2013-10-21 2014-10-20 新規ctlエピトープ4連結ペプチド
EP14856540.1A EP3061771B1 (en) 2013-10-21 2014-10-20 Novel four-ctl epitope-joined peptide

Publications (1)

Publication Number Publication Date
PL3061771T3 true PL3061771T3 (pl) 2020-10-19

Family

ID=52992831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14856540T PL3061771T3 (pl) 2013-10-21 2014-10-20 Nowy peptyd o czterech połączonych epitopach dla ctl

Country Status (19)

Country Link
US (1) US10137183B2 (pl)
EP (1) EP3061771B1 (pl)
JP (2) JP6211093B2 (pl)
KR (1) KR101913333B1 (pl)
CN (1) CN105658673B (pl)
AU (1) AU2014337643B2 (pl)
CA (1) CA2927817C (pl)
DK (1) DK3061771T3 (pl)
ES (1) ES2796301T3 (pl)
HU (1) HUE050164T2 (pl)
MX (1) MX2016004754A (pl)
MY (1) MY179119A (pl)
PH (1) PH12016500742B1 (pl)
PL (1) PL3061771T3 (pl)
PT (1) PT3061771T (pl)
RU (1) RU2636549C1 (pl)
SG (1) SG11201603165TA (pl)
TW (1) TWI651094B (pl)
WO (1) WO2015060235A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
US20200353070A1 (en) * 2018-01-22 2020-11-12 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Selective cd8-positive t cell-inducing vaccine antigen
JP6716801B2 (ja) * 2018-06-29 2020-07-01 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
BR112021008172A2 (pt) * 2018-11-02 2021-08-17 Taiho Pharmaceutical Co., Ltd. preparação em emulsão e método de preparo da mesma
EP4082563A4 (en) * 2019-12-26 2024-02-28 Taiho Pharmaceutical Co., Ltd. POST-OPERATIVE ADJUVANT THERAPY AGENT

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20080286228A1 (en) 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
EP0923940B1 (en) 1996-03-10 2008-09-03 Meiji Dairies Corporation Peptide-based immunotherapeutic agent for allergic diseases
JP4138073B2 (ja) 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
NZ508996A (en) 1998-06-25 2003-09-26 Kyogo Itoh Tumor antigen peptides derived from cyclophilin B
JP4436977B2 (ja) * 1998-08-28 2010-03-24 株式会社グリーンペプタイド 新規な腫瘍抗原タンパク質sart−3、およびその腫瘍抗原ペプチド
US6667037B1 (en) 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE464383T1 (de) * 1999-08-05 2010-04-15 Greenpeptide Co Ltd Tumor antigen
JP2003512057A (ja) 1999-10-19 2003-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Mage−a12抗原ペプチド及びその利用
WO2001041741A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
WO2002010396A1 (en) * 2000-07-28 2002-02-07 Mogam Biotechnology Research Institute Gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom
AU2002227498A1 (en) 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
JP4097178B2 (ja) * 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
US20060035291A1 (en) * 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
JP4484707B2 (ja) 2002-09-27 2010-06-16 昇志 佐藤 腫瘍抗原タンパク質及びその利用
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4579581B2 (ja) * 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
CA2567942A1 (en) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2006188507A (ja) 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
KR101385805B1 (ko) 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
JP5114403B2 (ja) * 2006-07-11 2013-01-09 株式会社グリーンペプタイド Hla−a3スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なsart3由来ペプチド
JP2008145715A (ja) * 2006-12-08 2008-06-26 Fujifilm Corp ポジ型感光性組成物、パターン形成方法、及び薄膜トランジスタアレイ基板
JP4972691B2 (ja) 2007-08-16 2012-07-11 株式会社グリーンペプタイド HLA−A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
CN101854945B (zh) 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
CA2804127A1 (en) 2010-07-07 2012-01-12 Green Peptide Co., Ltd. Cancer peptide vaccine
JP5911098B2 (ja) 2012-04-09 2016-04-27 国立研究開発法人情報通信研究機構 翻訳装置、およびプログラム
JP2014155132A (ja) 2013-02-13 2014-08-25 Murata Mfg Co Ltd 回路基板およびその製造方法
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ctlエピトープ5連結ペプチド

Also Published As

Publication number Publication date
PT3061771T (pt) 2020-05-06
CN105658673B (zh) 2019-07-26
CA2927817C (en) 2019-02-26
DK3061771T3 (da) 2020-07-13
JPWO2015060235A1 (ja) 2017-03-09
US20160235828A1 (en) 2016-08-18
MY179119A (en) 2020-10-28
KR20160055922A (ko) 2016-05-18
RU2636549C1 (ru) 2017-11-23
TW201601749A (zh) 2016-01-16
KR101913333B1 (ko) 2018-10-30
BR112016008254A2 (pt) 2017-09-26
ES2796301T3 (es) 2020-11-26
MX2016004754A (es) 2016-07-22
AU2014337643B2 (en) 2017-07-13
CA2927817A1 (en) 2015-04-30
SG11201603165TA (en) 2016-05-30
CN105658673A (zh) 2016-06-08
PH12016500742A1 (en) 2016-06-20
HUE050164T2 (hu) 2020-12-28
JP2017171678A (ja) 2017-09-28
EP3061771B1 (en) 2020-04-15
EP3061771A1 (en) 2016-08-31
WO2015060235A1 (ja) 2015-04-30
US10137183B2 (en) 2018-11-27
AU2014337643A1 (en) 2016-05-19
PH12016500742B1 (en) 2016-06-20
EP3061771A4 (en) 2017-08-16
JP6211093B2 (ja) 2017-10-11
TWI651094B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
HK1216757A1 (zh) 肽化合物
SG11201602889TA (en) Novel polypeptides
HRP20180452T1 (hr) Peptidi
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
HK1211596A1 (en) Peptide
GB201308057D0 (en) Protein
HK1198769A1 (en) Novel peptide
HK1211595A1 (en) Peptide
GB201315130D0 (en) Peptides
GB201401955D0 (en) Protein
GB201305465D0 (en) Novel peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201318941D0 (en) Novel polypeptides
GB201322749D0 (en) Cyclic peptide
GB201308191D0 (en) Peptide product
GB201308193D0 (en) Peptide product
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein